In the landscape of cancer research, the patient-derived xenograft (PDX) model stands as a pivotal tool for understanding tumour biology, predicting therapeutic responses, and guiding personalised medicine. By transplanting human tumour tissue into an immunocompromised mouse, researchers can study the growth, genetics, and drug sensitivity of individual tumours in a living organism. This extensive overview explores what a patient-derived xenograft is, how it is developed, where it fits among other models, and what the future holds for this influential approach.
What is a Patient-Derived Xenograft?
A patient-derived xenograft, often abbreviated as PDX, refers to a model created by implanting human tumour material into an immunodeficient host. Unlike traditional cell line xenografts, which use long-established cancer cell lines grown under artificial conditions, PDX models maintain the architectural organisation, heterogeneity, and microenvironmental signals of the original tumour. This fidelity is particularly valuable for studying how tumours evolve under therapeutic pressure and for identifying biomarkers of response or resistance.
Key features of Patient-Derived Xenograft models
- Preservation of tumour heterogeneity, including subclones and stromal components.
- Retention of histological architecture and gene expression patterns characteristic of the primary tumour.
- Variable engraftment depending on tumour type, stage, and the site of implantation.
- Potential for serial passaging to study tumour evolution over time.
PDX models have become broadly integrated into oncology research, enabling researchers to probe questions that are difficult to answer with traditional cell culture systems alone. By maintaining the complexity of human tumours in a living host, the study of pharmacodynamics, pharmacokinetics, and mechanism of action can be significantly enhanced.
Origins and Evolution of Patient-Derived Xenograft Models
The concept of xenografting human tissue into mice emerged decades ago, but the modern patient-derived xenograft framework as we know it developed in the early 2000s. Early efforts demonstrated that human tumours could be grown in mice with immunodeficiency, enabling in vivo studies that were previously impossible. Over time, refinements in mouse strains, surgical techniques, and tissue handling improved engraftment rates and model stability.
From solid tumours to haematological malignancies
Although initially focused on solid tumours, the PDX approach has expanded to include haematological cancers, including leukaemias and lymphomas. Each cancer type presents unique challenges; for instance, certain haematological malignancies may engraft more readily in specific mouse strains or require particular conditioning regimens. This diversification has broadened the utility of the patient-derived xenograft framework across cancer research disciplines.
How a Patient-Derived Xenograft Model Is Created
The creation of a patient-derived xenograft involves a sequence of precise steps designed to preserve the integrity of the human tumour while establishing a viable, long-term in vivo model. While protocols vary by lab and cancer type, the core principles are consistent across most PDX workflows.
Procurement and handling of human tumour tissue
With appropriate ethical approval and patient consent, fresh tumour tissue is obtained during surgical resections or biopsy. Timely delivery to the laboratory is critical to maintaining tissue viability. Upon receipt, tissue is usually divided into portions for engraftment and for molecular characterisation or cryopreservation. Gentle handling preserves cellular viability and preserves the heterogeneity that makes each PDX model unique.
Selection of an appropriate host mouse
Hosts are typically highly immunodeficient strains, such as NOD/SCID, NSG, or other variants designed to minimise rejection of human tissue. The choice of strain can influence engraftment efficiency, growth rate, and the homology of the tumour microenvironment. Some advanced models incorporate humanised immune systems to better recapitulate patient-specific immune interactions, though these systems add complexity and cost.
Engraftment and implantation sites
Tumours can be implanted subcutaneously or orthotopically (in the original anatomical site). Subcutaneous engraftment is technically straightforward and convenient for monitoring tumour growth, but orthotopic models may provide a more accurate representation of the tumour’s biology and interactions with surrounding tissues. The route of implantation, tumour size, and implantation site are all considered carefully to optimise engraftment and preserve clinically relevant features.
Validation and characterisation
Once engrafted, tumours are monitored for growth using calipers or imaging modalities. Molecular analyses, such as sequencing and transcriptomics, verify that the PDX retains the characteristics of the patient’s tumour. Researchers often compare histology, mutation status, and gene expression profiles between the primary tumour and the PDX to confirm fidelity. This validation is essential before the model is used for drug testing or mechanistic studies.
Passaging, banking, and sharing models
PDX models may be passaged into additional mice to expand cohorts or banked for long-term storage using cryopreservation. Proper banking ensures reproducibility and makes it possible for other researchers to access established models, enhancing collaborative research efforts. Each passage carries a risk of drift; therefore, periodic re-validation against the original tumour is important to maintain fidelity.
Applications of the Patient-Derived Xenograft in Oncology
The patient-derived xenograft model has wide-ranging applications in cancer research and precision medicine. By closely mirroring human tumours, PDX models support preclinical testing, biomarker discovery, and deeper mechanistic insights into drug response and resistance.
Preclinical evaluation of anticancer drugs
PDX models are widely used to screen the efficacy of new compounds and to explore optimal dosing strategies. By testing a drug across multiple PDX models representing diverse tumour biology, researchers can identify which molecular subtypes are most likely to benefit. This approach helps prioritise clinical development and reduce the risk of late-stage trial failures.
Biomarker discovery and patient stratification
One of the standout capabilities of patient-derived xenograft models is their utility in biomarker discovery. By correlating molecular features with therapeutic responses across a panel of PDX tumours, researchers can identify markers that predict sensitivity or resistance. This information supports the design of parallel or adaptive clinical trials and aids in patient stratification for personalised therapy.
Understanding resistance mechanisms
Resistance to therapy is a major challenge in oncology. The PDX framework enables investigators to study how tumours adapt to targeted therapies or chemotherapy over time. Serial sampling and re-treatment of PDX cohorts can reveal pathways driving resistance, enabling the development of combination strategies designed to overcome it.
Co-clinical trials and personalised medicine
In some research settings, patient-derived xenograft models are employed in parallel with patient treatment decisions—a concept known as co-clinical trials. These studies aim to rapidly translate insights from PDX experiments into clinical strategies for the donor patient and related cohorts. While not universally applicable to every cancer type or health service, this approach illustrates the potential real-time impact of PDX research on patient care.
Drug repurposing and combination therapies
PDX models facilitate exploration of existing drugs in new combinations that could yield synergistic effects. By testing various regimens across a spectrum of PDX tumours, researchers can identify promising strategies for faster clinical translation and reduced development timelines.
Advantages and Limitations of the Patient-Derived Xenograft
No model is perfect. The patient-derived xenograft offers substantial advantages, while certain limitations must be acknowledged when designing studies and interpreting results.
Advantages
- High fidelity to the patient tumour in terms of histology and genetics.
- Maintenance of intra-tumour heterogeneity, including subclones and microenvironmental interactions.
- Improved prediction of clinical drug responses compared with conventional cell line models.
- Utility for biomarker discovery and personalised medicine initiatives.
Limitations
- Absence or limited representation of the human immune system in many PDX models, which can affect immunotherapy studies.
- Practical demands: costs, logistics, and longer timelines relative to in vitro systems.
- Engraftment bias: some tumour types engraft more readily than others, potentially skewing model availability.
- Genetic drift with successive passages, underscoring the need for careful validation and documentation.
Ethical and Regulatory Considerations in PDX Research
Ethical governance is integral to patient-derived xenograft research. Institutions typically require robust informed consent processes, clear patient information, and approvals from ethical review boards. Moreover, regulatory frameworks guide the humane use of animals, including housing conditions, welfare monitoring, and endpoints that ensure minimisation of suffering. Transparent reporting and adherence to best practices help sustain public trust and scientific integrity in PDX studies.
Technical Considerations: Humanising the Mouse and the Tumour Microenvironment
Maximising the translational relevance of patient-derived xenograft models involves addressing the interplay between human tumours and the mouse host. Several strategies have emerged to enhance the human-like tumour microenvironment and immune context, while acknowledging practical constraints.
Humanised mouse models
Humanised mice are engineered to possess components of the human immune system. This approach enables more realistic studies of immunotherapies and tumour-immune interactions. However, humanised models are expensive and technically complex, and they can introduce additional variability that researchers must account for in experimental design.
Engraftment site and stromal components
Maintaining human stromal elements and extracellular matrix within the PDX can influence tumour growth and drug response. Techniques such as orthotopic implantation and selective preservation of human stromal tissue help preserve relevant microenvironmental cues, although complete recapitulation of the human tumour niche remains challenging.
Genomic fidelity and clonal evolution
Over time, the genetic landscape of a PDX can drift away from the original patient tumour. Serial genomic profiling across passages helps detect clonal shifts and informs decisions about the appropriate number of passages for any given study. Researchers often prioritise early-passage xenografts to retain maximum fidelity to the donor tumour.
PDX vs Other Models: Organotypic Cultures, Organoids and GEMMs
In the toolbox of cancer modelling, patient-derived xenograft models complement other approaches, each with distinct strengths and limitations. Understanding the relative advantages helps researchers select the most appropriate system for a given research question.
PDX versus organoids and spheroids
Organoids are three-dimensional in vitro cultures derived from patient tumours that can recapitulate many aspects of tissue architecture. They are valuable for high-throughput screening and mechanistic studies but lack the dynamic in vivo context of a living organism. Patient-derived xenografts, by contrast, preserve vascularisation, metabolism, and integrated systemic effects that influence drug response.
PDX versus genetically engineered mouse models (GEMMs)
GEMMs are engineered to carry specific mutations that drive tumour development in mice. They provide insight into genetic pathways and early tumourigenesis but may not accurately represent human tumour heterogeneity or the full spectrum of mutational events observed in patients. PDX models offer direct relevance to human tumours, albeit with the caveat of cross-species microenvironmental differences.
PDX in the context of clinical translation
Each model has a role in the translational pipeline. The PDX approach is particularly valued for testing therapeutic strategies on human tumour tissue while accounting for patient-specific biology, thereby enhancing the likelihood that findings will translate to the clinic.
Future Directions and Innovations in PDX Technology
The field of patient-derived xenograft research continues to evolve rapidly. Emerging directions aim to improve fidelity, throughput, and clinical relevance while reducing cost and complexity. Researchers are exploring new host strains, refined humanisation techniques, and integrative computational tools to interpret complex multi-omics data generated from PDX studies.
Humanised immune components and co-therapy models
Advancements in humanising the mouse immune system are enabling more robust studies of immunotherapies and combination regimens. Co-therapy models, which evaluate the interaction between targeted therapies and immune modulation, hold promise for personalised treatment strategies that reflect patient-specific biology.
In vitro–in vivo integration
Combining organoid systems with PDX models through co-clinical or hybrid approaches can provide complementary insights. Organoids offer rapid, high-throughput screening, while PDX models provide in vivo context. Integrated workflows can accelerate discovery and refine hypotheses before clinical testing.
Ethical and sustainability considerations
As the field grows, researchers continue to refine ethical frameworks and seek ways to minimise animal use through technology and data sharing. This includes improving methods to derive, culture, and bank patient-derived xenografts while safeguarding welfare and scientific value.
Practical Tips for Researchers Considering a Patient-Derived Xenograft Study
For teams contemplating the use of a patient-derived xenograft model, several practical considerations can inform planning and ensure robust, reproducible results.
Defining research questions and model selection
Clarify the scientific question and determine whether PDX is the most appropriate model. Consider tumour type, heterogeneity, immune involvement, and the expected translational relevance. Decide whether a single model suffices or a panel of PDX tumours is needed to capture biological diversity.
Ethics, consent, and governance
Ensure that patient consent covers the use of tissue for xenograft studies and that ethical approvals are in place. Establish clear data governance and tissue handling protocols, including anonymisation and long-term storage plans.
Resource planning and timelines
PDX work is resource-intensive. Plan for facility space, animal care, staff training, and the time needed from tissue procurement to experimental readouts. Budget for potential delays related to engraftment variability and validation steps.
Quality control and validation
Develop a robust validation plan that includes histopathology, genomic profiling, and, where feasible, proteomic analyses to confirm model fidelity. Establish acceptance criteria for proceeding with drug testing or mechanistic studies.
Data management and sharing
Implement a data management strategy to track model lineage, passage numbers, and experimental outcomes. Consider sharing validated PDX models through institutional repositories or collaborations to accelerate scientific progress while ensuring appropriate oversight.
Patient Perspectives and Clinical Relevance
PDX research has meaningful implications for patients and clinicians. By reflecting the complexity of individual tumours, PDX models contribute to understanding why some therapies succeed for a particular patient but not for others. Through biomarker discovery and co-clinical approaches, PDX studies can help tailor treatments to the molecular profile of a patient’s cancer, potentially improving outcomes and reducing exposure to ineffective therapies.
However, it is important to communicate that PDX models are a research tool and not a direct surrogate for clinical decision-making in individual patients. The translational value emerges when insights from PDX studies inform broader clinical strategies, trial design, and the discovery of predictive biomarkers that can be validated in human populations.
Glossary of Terms Related to Patient-Derived Xenograft
- Patient-Derived Xenograft (PDX): A model where human tumour tissue is implanted into an immunocompromised mouse to study cancer biology and therapy in vivo.
- Engraftment: The process by which transplanted human tumour tissue begins to grow in the host animal.
- Orthotopic: Implantation of a tumour into its original anatomical site.
- Subcutaneous: Implantation beneath the skin, usually for ease of monitoring tumour growth.
- Humanised mouse: A mouse engineered to contain components of the human immune system.
- Passage: The process of transferring tumours from one animal to another to expand the model.
- Fidelity: The degree to which the PDX mirrors the donor tumour’s biology and genetics.
- Clonal evolution: Changes in the genetic composition of tumour cells over time, which can occur during passage.
Concluding Thoughts on the Patient-Derived Xenograft Landscape
The patient-derived xenograft model remains a cornerstone of contemporary cancer research. Its ability to preserve the heterogeneity and architecture of human tumours makes it uniquely suited to interrogate drug responses, understand resistance, and drive personalised treatment concepts forward. While no model is a perfect replica of human disease, the continued refinement of PDX techniques, the emergence of humanised systems, and the integration with computational analytics are expanding the utility and reliability of this powerful research platform. For scientists, clinicians, and patients alike, the patient-derived xenograft framework offers a tangible pathway from bench to bedside, guiding more precise interventions and a deeper understanding of cancer biology.
